Conferences

August 26, 2024

EHA 2024: Ivosidenib for High-Risk MDS

August 05, 2024

MDS specialists from Spain shared how elritercept is helping low-risk MDS patients reduce anemia and iron overload symptoms.

July 02, 2024

Dr. El-Jawahri shared how palliative care can improve high-risk MDS patients’ quality of life and better prepare them for potential end-of-life care plans.

June 20, 2024

ASCO 2024: azacitidine for low- and intermediate-risk MDS

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 13, 2024

Explore key findings from the Cancer Experience Registry® study, revealing gaps in MDS patient knowledge and highlighting the need for improved education.

February 21, 2024

At ASH 2023, we had the privilege of interviewing Carmelo Gurnari from the Cleveland Clinic/University of Rome Tor Vergata.

February 20, 2024

This study focuses on patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who were exposed to chemotherapy and/or radiation therapy.

February 05, 2024

The study looks into Composite Complete Response (cCR) definitions introduced in the IWG 2023 criteria for patients with HR-Myelodysplastic Syndromes (HR-MDS).

January 31, 2024

VALIDATE is a multinational and international consortium dedicated to addressing crucial questions in the management of MDS patients.